{"id":"NCT03436693","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-15","primaryCompletion":"2021-01-21","completion":"2021-01-21","firstPosted":"2018-02-19","resultsPosted":"2024-07-15","lastUpdate":"2024-07-15"},"enrollment":308,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Nephropathy"],"interventions":[{"type":"DRUG","name":"Canagliflozin","otherNames":["TA-7284, Canaglu"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Canagliflozin 100mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo","primaryOutcome":{"measure":"Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104","timeFrame":"Week 104","effectByArm":[{"arm":"Canagliflozin 100mg","deltaMin":18.2,"sd":null},{"arm":"Placebo","deltaMin":29.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":26,"countries":["Japan"]},"refs":{"pmids":["35861630","38770818"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":154},"commonTop":["Nasopharyngitis","Hypoglycaemia","Blood glucose decreased","Back pain","Constipation"]}}